Short answer
Evolus, Inc. (EOLS) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Evolus, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026
- Detailed results furnished in Exhibit 99.1 for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $84.1M, up 21%, with toxin revenue $75.2M and HA gel revenue $8.9M
- Adjusted EBITDA $4.7M versus $(7.9)M, marking the third consecutive positive quarter and $12.6M improvement
- 2026 revenue guidance raised to $330M-$337M; adjusted gross margin outlook increased to 67.0%-67.5%
- Profhilo partnership adds a third U.S. injectable vertical, with estimated peak annual revenue exceeding $100M and U.S. commercialization anticipated in 2030
- Cash $45.2M plus approximately $120M non-dilutive capacity; long-term debt increased to $156.7M at June 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Evolus, Inc. 8-K filings
Get the next EOLS 8-K as it lands
Follow EOLS for push alerts, or ask the research agent what this filing means.